Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Notice how fast the discounted stock is being sold -- none of the investors getting discounted stock appear to want to hold onto it."
Yes I have, and have been commenting on it here as it's obvious $CYDY common equity is NOT an investment, it's a stock selling operation at this point.
A lot of entities, lenders, the market makers, the clearing houses, the webinar hosts, the paid pumps, PIPE bookrunners, etc., all make a cut at the toxic lending feeding troughs. Everyone gets a cut EXCEPT the retail market participants.
Wow, 12 and 12 with no markup on the warrants AND have 10 year life. Those brokers will sacrifice many lambs for a 12% cash commission. For those who are new here, a reputable firm charges 2-4%. Hence why Paulson brokers have multiple disclosures.
That is a really rich deal.
I'm not part of the bankruptcy narrative group, as toxic lending and warrants can keep the pig alive as long as there are retail level dreamers willing to pay retail market price for worthless common equity.
Actually, that’s a past narrative, not a “next” one. We’ve been hearing “bankrupt soon” for quite some time now.
Below $1 is the next "narrative"..
If one doesn't have warrants with their stock offering for $CYDY, then yes you are being scammed.
Because I think I'm getting scammed on my "loyal customer" bonus payment.
$CYDY has been a PIPE book runner's dream as they have been selling worthless paper to unsuspecting OTC retail dreamers for a long time.
Leronlimab is simply means to the end of selling stock with the assistance of toxic lenders and warrant holders enriching themselves in the process.
$UNRV is making progress fixing the balance sheet.
"How to sell is the secret."
Which is exactly what the toxic lenders with discounted shares and warrants have been doing in "secret".
Nader's Big Picture is to always be pumping to help the toxic lenders and warrant holders sell stock.
Paulson makes more than 10% profits when income from all sources including fees and spreads are taken into account.
It's an easy business and IMO easier with social media.
The "shorts" are in reality "longs" selling as I've been saying all along. Look at the dilution and constant need to increase the share count, but the SEC is onto that trick and holding up declaring the shelf offering effective.
This is how toxic financing works, and with the proper disclosures and regulatory filings its legal.
Ask a PIPE bookrunner about the special operations that take place in discounted deals with warrants.
So...which is it a proven miracle or "just beginning"?
CytoDyn is just beginning to show outstanding results.
The question is… how much is
CYDY worth?
$UNRV cleaning up more of $TRTC's past garbage....
Unrivaled Brands Announces Agreement to Sell
Inoperative Dyer Property for $13.4 Million
The stupidity of timing of the insider transactions simply hillarious!
The "pumps" debunk their own case all the time....Dr. Jay is a paid shill ...FACT!
Not everyone plays well in a team environment.
Indeed, blessings to the excellent shared DD.
After 2 decades in biotech, $AVXL is one of my last large "risk" plays before I commit to a more conservative asset allocation.
I don't do DD anymore, my research team does it for me.
On December 14, 2020 $AVXL released this: https://www.anavex.com/post/anavex-life-sciences-announces-anavex-2-73-meets-primary-and-secondary-endpoints-in-clinical-trial
Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary Endpoints in Clinical Trial
Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I
Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms and correlated with changes in biomarker (glutamate) of disease pathology
Key milestone met to advance regulatory approval pathway for adult patients with Rett syndrome
$CYDY challenges the 52 week low.
The situation will remain the same for next week as the sales pitch is rapidly losing effectiveness, but it is helping the toxic lenders and warrant holders unload discounted shares into the volume.
Way too late for that, leronlimab needs $CYDY to go through a good old OTC "Wash, Rinse, Repeat"
CYDY needs a major overhaul in leadership. There has been so much the investors have been misled on by Nader and Kelly.
© 2021 InvestorsHub.com, Inc.
I didn't follow the dose schedule excuses, but was Dr. Jacob the cause or the solution?
March 13,2020 : "Jacob P. Lalezari, M.D. as Interim Chief Medical Officer. Dr. Lalezari is currently leading CytoDyn’s immediate preparations to initiate a coronavirus (COVID-19) clinical trial and the Company will file a modified trial protocol on Friday, March 13."
Great, but it's the long share selling warrant holders and toxic lenders that are executing the sell pressure.
Personally I like this news as I thought working the daily "Regulation SHO" report back in my day was simply regulatory busy work with zero net effect at enforcement of the spirit of the rule. But I digress.
He wisely never owned $CYDY.
Lalezari looks nervous. He would know more about the inner workings of CYDY than us rando bloggers. Hes the proverbial canary in the coal mine. His only source of income and he writes a letter begging.
ps-Quest Research receives financial support for studies with leronlimab on HIV and cancer. I
don’t own/never owned any stock or have any other financial stake in CytoDyn.
Short interest is now down to 6.3% of shares outstanding and is historically low for $AVXL.
This is not a squeezable percentage and IMO increases in $AVXL's price will be from "organic" market demand.
I know bookrunners, toxic lenders and OTC "chop shops" get paid whenever volume is created.
A simple Google search found Jacob Lalezari.
https://www.questclinical.com/dr-jay
Maybe the legal entity search didn't include all "dba", doing business as names.
It appears he had ONE job, and that one job was to being paid to produce reports for $CYDY.
https://www.questclinical.com/study-participation
Thinking he is as a reliable source is laughable!!!
Tomorrow will bring in a new 52 week low.
2 PR's and nothing, the sales pitch is rapidly losing effectiveness, but it is helping the toxic lenders and warrant holders unload cheap shares onto remaining retail dreamers.
Dr. Jay Lalezari's employer receives funds for his salary from $CYDY... quite the conflict of interest to be objective.
Quest Research receives financial support for studies with leronlimab on HIV and cancer. I don’t own/never owned any stock or have any other financial stake in CytoDyn.
Trading today looks like the book runners had a hard time controlling the sell off.
Wonder what's left on the pump story agenda?
Better luck tomorrow.
Warrant holders and owners of discounted stock made some nice profits selling into today's pump story.
"who chases a worldwide pandemic for two years in 4 trials and can't enroll them"
The same type of company that pumps acceptance to have a meeting to further ask for permission to underpower the study. That way the company can have an excuse for the inevitable failure and scapegoat anything besides itself.
Unrivaled Brands Announces Grand Opening of People’s Downtown Los Angeles Location
https://ir.unrivaledbrands.com/news-events/press-releases/detail/321/unrivaled-brands-announces-grand-opening-of-peoples
Special operatives at the primary broker are working hard to convince shareholders not to sell.
Paulson and crew have a rough job I'm sure.
Company CRO asks for permission to underpower study so company can have an excuse for the inevitable failure.
ANVISA will probably deny the request, as it's simply bad science to deliberately underpower a study.
ANVISA has authorized CytoDyn to submit the requested changes.
Most pathetic attempt at a pump to date!
....received its agreement to modify the CD16 trial for critically ill COVID-19 patients. ANVISA has authorized CytoDyn to submit the requested changes.
You are correct in that the shares were in exchange from the revenue producing mergers.
Nobody got something for nothing. I would have pointed it out.
The darkness is $CYDY being sucked into an OTC black hole, zero light will escape.
We are in the darkness now but not for much longer